Last reviewed · How we verify
NCT05156541: ING-HPV-1
Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts
Phase 3 trial testing Interferon gamma human recombinant (IFN-G) in Human Papillomavirus Infection in 30 participants. Completed in 15 July 2010.
30 June 2010
Quick facts
| Lead sponsor | SPP Pharmaclon Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 18 May 2009 |
| Primary completion | 30 June 2010 |
| Estimated completion | 15 July 2010 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Interferon gamma human recombinant (IFN-G) — full drug profile →
Conditions studied
- Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →
- Anogenital Warts — all drugs for Anogenital Warts →
Sponsor
SPP Pharmaclon Ltd. — full company profile →
Who can join
Adults 18 to 50, any sex, with Human Papillomavirus Infection or Anogenital Warts. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05156541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Interferon gamma human recombinant (IFN-G)
Trials testing the same drug.
- NCT05054114 — Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19 · NA · completed
- NCT05386446 — Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19 · completed
Other recruiting trials for Human Papillomavirus Infection
Currently open trials in the same condition.
- NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
- NCT06598475 — Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve · NA · recruiting
- NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
- NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
- NCT06498661 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · NA · recruiting
Other SPP Pharmaclon Ltd. trials
Trials by the same sponsor.
- NCT06118619 — A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis · unknown
- NCT05359315 — Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis · unknown
- NCT05054114 — Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19 · NA · completed
- NCT05386446 — Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19 · completed
- NCT05386459 — Study of the Use of the Drug Ingaron in Patients With COVID-19 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05156541 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SPP Pharmaclon Ltd.
- Last refreshed: 14 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05156541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing